UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Is Puma Biotechnology a Buy? | The Motley Fool
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib | Nasdaq
Puma and CANBridge cancel licensing deal for $20m
Puma Biotechnology Seen as Takeover Target After Strong Cancer Drug Data - TheStreet
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Opinion: 15 biotech stocks to put on your watch list now - MarketWatch
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotech's new cancer drug Nerlynx suffered a terrible quarter. What gives? | Fierce Pharma
Puma Biotechnology
A Licensing Agreement Won't Protect This Biotech From A Takeover | Investor's Business Daily
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Does Puma's quick Nerlynx launch play into its buyout prospects? | Fierce Pharma
The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology | $PBYI Stock | Shares Climb Up as Company Announced FDA Approval for NERLYNX - Warrior Trading News
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
10 Takeover Targets of 2018
